TY - JOUR
T1 - Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study
AU - the MASK group
AU - Menditto, Enrica
AU - Costa, Elisio
AU - Midão, Luis
AU - Bosnic-Anticevich, Sinthia
AU - Novellino, Ettore
AU - Bialek, Slawomir
AU - Briedis, Vitalis
AU - Mair, Alpana
AU - Rajabian-Soderlund, Rojin
AU - Arnavielhe, Sylvie
AU - Bedbrook, Anna
AU - Czarlewski, Wienczyslawa
AU - Annesi-Maesano, Isabella
AU - Anto, Josep M.
AU - Devillier, Philippe
AU - de Vries, Govert
AU - Keil, Thomas
AU - Sheikh, Aziz
AU - Orlando, Valentina
AU - Larenas-Linnemann, D. sirée
AU - Cecchi, Lorenzo
AU - de Feo, Giulia
AU - Illario, M.
AU - Stellato, Cristiana
AU - Fonseca, Joao
AU - Malva, Joao
AU - Morais-Almeida, Mario
AU - Pereira, Ana Maria
AU - Todo-Bom, Ana Maria
AU - Kvedariene, Violeta
AU - Valiulis, Arunas
AU - Bergmann, Karl Christian
AU - Klimek, Ludger
AU - Mösges, Ralph
AU - Pfaar, Oliver
AU - Zuberbier, Torsten
AU - Cardona, Vicky
AU - Mullol, Joaquim
AU - Papadopoulos, Nikos G.
AU - Prokopakis, Emmanuel P.
AU - Bewick, Mike
AU - Ryan, Dermot
AU - Roller-Wirnsberger, Regina E.
AU - Tomazic, Peter Valentin
AU - Cruz, Alvaro A.
AU - Kuna, Piotr
AU - Samolinski, Boleslaw
AU - Fokkens, Wytske J.
AU - Reitsma, Sietze
AU - Hellings, Peter W.
PY - 2019/4
Y1 - 2019/4
N2 - Background: Mobile technology may help to better understand the adherence to treatment. MASK-rhinitis (Mobile Airways Sentinel NetworK for allergic rhinitis) is a patient-centred ICT system. A mobile phone app (the Allergy Diary) central to MASK is available in 22 countries. Objectives: To assess the adherence to treatment in allergic rhinitis patients using the Allergy Diary App. Methods: An observational cross-sectional study was carried out on all users who filled in the Allergy Diary from 1 January 2016 to 1 August 2017. Secondary adherence was assessed by using the modified Medication Possession Ratio (MPR) and the Proportion of days covered (PDC) approach. Results: A total of 12 143 users were registered. A total of 6 949 users reported at least one VAS data recording. Among them, 1 887 users reported ≥7 VAS data. About 1 195 subjects were included in the analysis of adherence. One hundred and thirty-six (11.28%) users were adherent (MPR ≥70% and PDC ≤1.25), 51 (4.23%) were partly adherent (MPR ≥70% and PDC = 1.50) and 176 (14.60%) were switchers. On the other hand, 832 (69.05%) users were non-adherent to medications (MPR <70%). Of those, the largest group was non-adherent to medications and the time interval was increased in 442 (36.68%) users. Conclusion and clinical relevance: Adherence to treatment is low. The relative efficacy of continuous vs on-demand treatment for allergic rhinitis symptoms is still a matter of debate. This study shows an approach for measuring retrospective adherence based on a mobile app. This also represents a novel approach for analysing medication-taking behaviour in a real-world setting.
AB - Background: Mobile technology may help to better understand the adherence to treatment. MASK-rhinitis (Mobile Airways Sentinel NetworK for allergic rhinitis) is a patient-centred ICT system. A mobile phone app (the Allergy Diary) central to MASK is available in 22 countries. Objectives: To assess the adherence to treatment in allergic rhinitis patients using the Allergy Diary App. Methods: An observational cross-sectional study was carried out on all users who filled in the Allergy Diary from 1 January 2016 to 1 August 2017. Secondary adherence was assessed by using the modified Medication Possession Ratio (MPR) and the Proportion of days covered (PDC) approach. Results: A total of 12 143 users were registered. A total of 6 949 users reported at least one VAS data recording. Among them, 1 887 users reported ≥7 VAS data. About 1 195 subjects were included in the analysis of adherence. One hundred and thirty-six (11.28%) users were adherent (MPR ≥70% and PDC ≤1.25), 51 (4.23%) were partly adherent (MPR ≥70% and PDC = 1.50) and 176 (14.60%) were switchers. On the other hand, 832 (69.05%) users were non-adherent to medications (MPR <70%). Of those, the largest group was non-adherent to medications and the time interval was increased in 442 (36.68%) users. Conclusion and clinical relevance: Adherence to treatment is low. The relative efficacy of continuous vs on-demand treatment for allergic rhinitis symptoms is still a matter of debate. This study shows an approach for measuring retrospective adherence based on a mobile app. This also represents a novel approach for analysing medication-taking behaviour in a real-world setting.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063011308&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30597673
U2 - https://doi.org/10.1111/cea.13333
DO - https://doi.org/10.1111/cea.13333
M3 - Article
C2 - 30597673
SN - 0954-7894
VL - 49
SP - 442
EP - 460
JO - Clinical and experimental allergy
JF - Clinical and experimental allergy
IS - 4
ER -